Clinical Study Results
Did any adverse reactions happen during this study?
Dapagliflozin Placebo
(out of 39 participants) (out of 33 participants)
How many participants had
17.9% (7) 15.2% (5)
adverse reactions?
How many participants had
0.0% (0) 0.0% (0)
serious adverse reactions?
How many participants
stopped getting study
2.6% (1) 0.0% (0)
treatment because of adverse
reactions?
What serious adverse reactions happened during this study?
None of the participants had serious adverse reactions in this study.
What adverse reactions happened during this study?
The most common adverse reactions are shown in the table below. These happened in 2 or
more participants. There were other adverse reactions but these happened in fewer participants.
Dapagliflozin Placebo
(out of 39 participants) (out of 33 participants)
Nausea 5.1% (2) 0.0% (0)
Fungal infection 2.6% (1) 3.0% (1)
Urinary tract infection 2.6% (1) 3.0% (1)
Frequent passing of large
2.6% (1) 3.0% (1)
amounts of urine
Frequent urination
2.6% (1) 3.0% (1)
during the day
Painful or difficult urination 2.6% (1) 3.0% (1)
How has this study helped patients and researchers?
This study helped researchers learn more about dapagliflozin in young people with T2DM.
Researchers look at the results of many studies to decide which treatments work best and are
safest. This summary shows only the main results from this one study. Other studies may provide
new information or different results.
Further clinical studies with dapagliflozin are ongoing.
7